|
|
Volumn 100, Issue 1, 2013, Pages 276-285
|
|
Meeting report: 26th International Conference on Antiviral Research
|
|
Author keywords
Antiviral therapy; Hepatitis B; Hepatitis C; Herpesviruses; Human immunodeficiency virus
|
|
Indexed keywords
9 (2,3 DIHYDROXYPROPYL)ADENINE;
ACICLOVIR;
ADEFOVIR;
ADEFOVIR DIPIVOXIL;
ANTIVIRUS AGENT;
CENICRIVIROC;
CIDOFOVIR;
CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER;
COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;
DENGUE VACCINE;
DUVIRA;
EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;
ELVITEGRAVIR;
EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL;
EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;
FESTINAVIR;
GANCICLOVIR;
IDOXURIDINE;
MICRORNA 122;
MIRAVIRSEN;
NUCLEOSIDE DERIVATIVE;
STAVUDINE;
TENOFOVIR;
TENOFOVIR ALAFENAMIDE;
UNCLASSIFIED DRUG;
VALACICLOVIR;
VIRUS RNA;
ZIDOVUDINE;
ANTIVIRAL THERAPY;
AWARDS AND PRIZES;
COMPARATIVE EFFECTIVENESS;
COMPASSIONATE USE;
CONFERENCE PAPER;
CYTOMEGALOVIRUS INFECTION;
CYTOMEGALOVIRUS RETINITIS;
CZECH REPUBLIC;
CZECHOSLOVAKIA;
DNA VIRUS INFECTION;
DRUG APPROVAL;
DRUG BLOOD LEVEL;
DRUG EFFICACY;
DRUG HALF LIFE;
DRUG RESEARCH;
DRUG SAFETY;
HEPATITIS B;
HERPES LABIALIS;
HERPES SIMPLEX;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
INFECTION PREVENTION;
LIVER FIBROSIS;
MITOCHONDRIAL TOXICITY;
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
RNA CAPPING;
RNA SYNTHESIS;
SEROCONVERSION;
SYMPOSIUM;
TREATMENT RESPONSE;
UNSPECIFIED SIDE EFFECT;
VIRUS INFECTION;
ANIMAL;
CHEMISTRY;
CLINICAL TRIAL (TOPIC);
DRUG DESIGN;
DRUG EFFECT;
HEPATITIS C;
HERPES VIRUS;
HUMAN IMMUNODEFICIENCY VIRUS;
VIRAL PHENOMENA AND FUNCTIONS;
VIROLOGY;
VIRUS;
CYTOMEGALOVIRUS;
HEPATITIS C VIRUS;
HUMAN IMMUNODEFICIENCY VIRUS;
RNA VIRUSES;
ANTIVIRAL THERAPY;
HEPATITIS B;
HEPATITIS C;
HERPESVIRUSES;
HUMAN IMMUNODEFICIENCY VIRUS;
ANIMALS;
ANTIVIRAL AGENTS;
CLINICAL TRIALS AS TOPIC;
DRUG DESIGN;
HUMANS;
VIRUS DISEASES;
VIRUS PHYSIOLOGICAL PHENOMENA;
VIRUSES;
|
|
EID: 84884304405
PISSN: 01663542
EISSN: 18729096
Source Type: Journal
DOI: 10.1016/j.antiviral.2013.08.006 Document Type: Conference Paper |
|
Times cited : (9)
|
|
References (2)
|
